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Neurobiology of Disease
Reduced Reelin Expression Accelerates Amyloid- Plaque
Formation and Tau Pathology in Transgenic Alzheimer’s
Disease Mice
Samira Kocherhans,1* Amrita Madhusudan,1* Jana Doehner,1* Karin S. Breu,1 Roger M. Nitsch,2 Jean-Marc Fritschy,1
and Irene Knuesel1
1Institute of Pharmacology and Toxicology, University of Zurich, CH-8057 Zurich, Switzerland, and 2Division of Psychiatry Research, University of Zurich,
CH-8008 Zurich, Switzerland
In addition to the fundamental role of the extracellular glycoprotein Reelin in neuronal development and adult synaptic plasticity,
alterations in Reelin-mediated signaling have been suggested to contribute to neuronal dysfunction associated with Alzheimer’s disease
(AD). In vitro data revealed a biochemical link between Reelin-mediated signaling, Tau phosphorylation, and amyloid precursor protein
(APP) processing. To directly address the role of Reelin in amyloid- plaque and Tau pathology in vivo, we crossed heterozygous Reelin
knock-outmice (reeler) with transgenic ADmice to investigate the temporal and spatial AD-like neuropathology.We demonstrate that a
reduction in Reelin expression results in enhanced amyloidogenic APP processing, as indicated by the precocious production of
amyloid- peptides, the significant increase in number and size of amyloid- plaques, as well as age-related aggravation of plaque
pathology in double mutant compared with single AD mutant mice of both sexes. Numerous amyloid- plaques accumulate in the
hippocampal formation and neocortex of doublemutants, precisely in layers with strongest Reelin expression and highest accumulation
of Reelin plaques in aged wild-type mice. Moreover, concentric accumulations of phosphorylated Tau-positive neurons around
amyloid- plaques were evident in 15-month-old double versus single mutant mice. Silver stainings indicated the presence of neurofi-
brillary tangles, selectively associated with amyloid- plaques and dystrophic neurites in the entorhinal cortex and hippocampus. Our
findings suggest that age-related Reelin aggregation and concomitant reduction in Reelin-mediated signaling play a proximal role in
synaptic dysfunction associated with amyloid- deposition, sufficient to enhance Tau phosphorylation and tangle formation in the
hippocampal formation in aged Reelin-deficient transgenic ADmice.
Introduction
Alzheimer’s disease (AD) is characterized by progressive cogni-
tive decline and severe neurodegeneration (Savla and Palmer,
2005). Neuropathological hallmarks include neurofibrillary tan-
gles, consisting of hyperphosphorylated Tau (Grundke-Iqbal et
al., 1986) and senile plaques, mainly composed of amyloid-
peptides (Glenner andWong, 1984), the amyloidogenic cleavage
product of amyloid precursor protein (APP) (Estus et al., 1992;
Haass et al., 1992). Nonamyloidogenic cleavage produces frag-
ments with neuroprotective and transcriptional functions
(Furukawa et al., 1996; Gao and Pimplikar, 2001; von Rotz et al.,
2004). Rare early-onset AD is caused by mutations in app or
presenilin1/2 genes, all favoring amyloidogenic APP processing
(Goate et al., 1991; Levy-Lahad et al., 1995; Rogaev et al., 1995;
Sherrington et al., 1995). No apparent familial segregation is ev-
ident in the frequent late-onset AD cases. Combinations of ge-
netic, such as apolipoprotein E (ApoE) 4, and nongenetic risk
factors likely determine disease predisposition, age of onset, and
progression (Bertram and Tanzi, 2008). The effect of ApoE4 in
late-onset AD neuropathology remains to be elucidated. ApoE
isoforms bind to neuronal lipoprotein receptors, involved in a
variety of brain functions (Herz, 2009), indirectly implicating
ApoE receptors in AD pathophysiology. Two, including very-
low-density lipoprotein receptor (VLDLR) and ApoE receptor 2
(ApoER2), bind also the extracellular signalingmolecule Reelin, a
conserved glycoprotein required for neuronal migration and po-
sitioning during development (D’Arcangelo et al., 1995). In adult
neurons, Reelin-mediated signaling modulates synaptic NMDA re-
ceptor activity and is required for learning andmemory (Weeber et
al., 2002; Beffert et al., 2005, 2006a; Chen et al., 2005; Qiu et al.,
2006; Qiu and Weeber, 2007). In addition to its role in synaptic
plasticity and mnemonic functions, Reelin-mediated signaling
controls several AD-relevant pathways: it inhibits key mediators
of Tau phosphorylation (Hiesberger et al., 1999; Beffert et al.,
2002, 2004; Ohkubo et al., 2003) and decreases amyloidogenic
APP processing in vitro (Hoe et al., 2006; Hoe and Rebeck, 2008),
potentially mediated by direct Reelin–APP interactions (Hoe et
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al., 2009). In ADpatients, increased proteolytic Reelin fragments,
Reelin depletion in the entorhinal cortex (Sa´ez-Valero et al.,
2003; Botella-Lo´pez et al., 2006; Chin et al., 2007), and significant
differences in two RELN polymorphisms have been described
previously (Seripa et al., 2008).
We have reported in aged rodents and nonhuman primates a
pronounced reduction of Reelin-expressing interneurons and
concomitant accumulation of Reelin in amyloid-like deposits,
colocalizing with proteolytic APP fragments and associated with
a reduction in basal forebrain projection neurons that selectively
target Reelin-positive hippocampal interneurons (Knuesel et al.,
2009; Madhusudan et al., 2009; Doehner et al., 2010). The course
and magnitude of the plaque load correlated with cognitive per-
formance and was modulated by exacerbated inflammatory re-
sponses and genetic mutations favoring A peptide production
(Knuesel et al., 2009). Based on these findings, we hypothesized
that reduced Reelin-dependent signaling is a critical upstream
factor able to promote amyloidogenic APP processing and Tau
hyperphosphorylation. We directly tested this putative associa-
tion by characterizingAD-like neuropathology in the offspring of
transgenic ADmice crossed with heterozygous reelermice in bio-
chemical, histological, and immunohistochemical experiments
across aging.
Materials andMethods
Animals. All procedures were approved by the local authorities of the Can-
tonalVeterinaryOffice inZurich.All animalswerehoused ingroupsof three
to four in anoptimized in-househygiene area (OptimierterHygienebereich,
University of Zurich Irchel, Zurich, Switzerland) under 12 h day/night cycle
and ad libitum food and water. Heterozygous reeler (B6C3Fe-a/a-Relnrl/)
mice were obtained from The Jackson Laboratory and crossed with trans-
genic animals expressing the human APP695 gene containing the Swedish
(K670NM671L) andArcticmutations (E693G) in aC57BL/6 background
(Knobloch et al., 2007). The F1 offspring demonstrated Mendelian inheri-
tance, carryingoneof the followinggenotypes at expected frequencies: reln/
;appwt (wt, 28.6%), reln/;appwt (reln, 26.1%), reln/;tghappswe,arc (app,
27.6%), and reln/;tghappswe,arc (reln/app, 17.7%). Genotype determina-
tion was done with postmortem tail biopsies using the following primers to
detect the mutant reln gene product (363 bp): forward, 5-TAATCTG-
TCCTCACTCTGCC-3, and reverse, 5-TGCATTAATGTGCAGTGT-3.
The presence of a human 180 bp app gene product was confirmed with the
following primers: 5-CAGAACTGAACCATTTCAACCGAGC-3 and 5-
TCAGTGGGTACCTCCAGCGCCCGA-3. The number of animals used in
this study is summarized inTable 1.
Mouse brain tissue preparation.Animals were deeply anesthetized with
Nembutal (40 mg/kg, i.p.). The tissue was perfusion fixed and processed
as described previously (Knuesel et al., 2009; Doehner et al., 2010). Ran-
dom sampled serial sections were collected throughout the hippocampal
formation starting at bregma level0.85 to3.5 and stored at20°C in
cryoprotectant solution until immunohistochemical or histological eval-
uations (Knuesel et al., 2009).
Immunohistochemistry. A 15 min pepsin pretreatment (0.15 mg/ml in
0.2NHCl at 37°C) was applied to all the free-floating sections for epitope
unmasking and reduction of nonspecific staining (Doehner et al., 2010).
Sections were then briefly washed with PBS, pH 7.4, and processed for
immunohistochemistry. The following antibodies were used: mouse
anti-rodent Reelin (clone G10; Millipore; MAB364; 1:1000), rabbit
anti-human -amyloid (1-40/1-42; Millipore; AB5076; 1:2000),
mouse anti-human -amyloid (1-17; clone 6E10; Covance; SIG-
39320; 1:2000), mouse anti-mouse NeuN (clone A60; Millipore;
MAB377; 1:1000), rabbit anti-human phosphorylated Tau (phospho-
T205; Abcam; ab4841; 1:1000), rabbit anti-rat 1-syntrophin [poly-
clonal affinity purified serum; 1:500 (Haenggi et al., 2005)], and rat
anti-mouse CD68 (AbD Serotec; MCA 341R; 1:2000). After completion
of the double immunofluorescence stainings, GFAP-positive astrocytes
were visualized with direct immunofluorescence using Cy3-conjugated
rabbit anti-GFAP IgG (kindly provided by Wolfgang Ha¨rtig, University
of Leipzig, Leipzig, Germany) (at 10 g/ml in Tris buffer, pH 7.4, con-
taining 2% BSA and 10% normal rabbit serum). For the nuclear coun-
terstaining, sections were incubated for 5 min in 10 nM SYTOX green
nucleic acid stain (Invitrogen) dissolved in PBS. Thioflavin S counter-
staining involved 10 min incubation in filtered 1% aqueous Thioflavin S
(Sigma-Aldrich) solution at room temperature, followed by two washes
for 5min in 80%EtOH, 5min wash in 95%EtOH, and three times 5min
washes in distilled water. Brain sections were then air-dried in the dark
and mounted with aqueous permanent mounting medium (Dako).
Double and triple immunofluorescence labelings were visualized by con-
focal microscopy (LSM-710; Zeiss) using a 40 [numerical aperture
(NA), 1.3] and sequential acquisition of separate channels. Z-stacks of
consecutive optical sections (6–12; 512  512 pixel; spaced 1 m in z)
were acquired at a magnification of 0.11–0.22 m/pixel. For visual dis-
play, Z-sections of all channels were summed and projected in the
z-dimension (maximal intensity) and merged using the image analysis
software Imaris (Bitplane). Cropping of images and adjustments of
brightness and contrast were identical for each labeling and done using
Adobe Photoshop.
Silver staining. For the detection of dystrophic neurites, extracellular
and intracellular proteinaceous aggregates, we used the FD NeuroSilver
Kit II (FD NeuroTechnologies). Free-floating perfusion-fixed brain
slices (40 m thick) prepared for normal immunohistochemistry were
processed according to the manufacturer’s instruction. Control sections
obtained from adult wild-type (wt) mice that received unilateral intra-
hippocampal injections of kainic acid, a procedure that results in rapid
degeneration of hippocampal interneurons and CA1 pyramidal cells
(Knuesel et al., 2002), served as controls.
Quantification of reactive astrocytes, microglia activation, and colocal-
ization between Thioflavin S, 1-syntrophin, and A.Quantitative analy-
ses of the immunohistochemical stainings were done on one randomly
selected hemisphere and performed blind to the genotype of the animals.
Eight single- (GFAP/CD68) or Z-stacks (A/ThioS/1-syn) of digital
images from six to eight brain sections per genotype and age (n 4–6)
were acquired in neocortical areas including LI to LVI, lateral entorhinal
cortex, and hippocampus, focusing on the CA1 stratum lacunosummo-
leculare. Area fractions of the GFAP- or CD68-immunoreactive cells,
Thioflavin S, anti-A, and anti-1-syntrophin immunoreactivity (IR)
were quantified using a fixed threshold algorithm of ImageJ software.
Colocalization of Thioflavin S- and A-immunoreactive signals in
amyloid- plaques in the same brain areas were measured on projected
Z-sections. Red and green channelswere first individually segmented and
then analyzed with regard to pixel overlap within outlined plaques using
a colocalization plug-in of ImageJ. Signals obtained from the green chan-
nel were set as 100%. To examine a putative preferential vascular associ-
ation of amyloid- plaques in reln/app mice, we measured using the
same approach the degree of pixel colocalization between1-syntrophin
and A IR with respect to the Thioflavin S signals, again set as 100%.
Table 1. Animals used
Genotype Abbreviation Age (months) No./experiment
reln/; appwt wt 3 4 IHC
6 5 IHC
9 6 IHC
reln/; appwt reln 3 4 IHC
6 4 IHC
9 9 IHC
reln/; tghappswe,arc app 3 4 IHC
6 4 IHC
9 8 IHC/8 WB
15 3 IHC
reln/; tghappswe,arc reln/app 3 4 IHC
6 4 IHC
9 8 IHC/8 WB
15 3 IHC
IHC, Immunohistochemistry, including DAB immunoperoxidase and fluorescence, as well as silver staining; WB,
Western blotting and ELISA.
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Quantification of NeuN-positive neurons and
Reelin- and A-positive plaque segregation.
Quantitative analysis of the neuronal density
associated with amyloid- plaques as well as
the Reelin/A plaque segregation in 9- and 15-
month-old mice were performed on one ran-
domly selected hemisphere in a blinded
fashion. Eight single (NeuN density) or
Z-stacks (Reelin/A plaque segregation) digi-
tal images from four brain sections per geno-
type and age (n  6, 9 months; n  3, 15
months) were acquired in the neocortex (mo-
tor and somatosensory areas) as well as in the
lateral entorhinal cortex. The numerical den-
sity of NeuN-positive neurons around plaques
was assessed using a threshold algorithm using
ImageJ software to individually outline and
quantify the number of cells in 512 512 pixel
images. Colocalization of Reelin- and A-
immunoreactive signals in extracellular plaques
were measured on projected Z-sections in LI of
the lateral entorhinal cortex.Redandgreenchan-
nels were first individually segmented and then
analyzed with regard to pixel overlap and segre-
gation within outlined individual plaques using
the colocalization plug-in of ImageJ. Signals ob-
tained from both channels (Reelin and A IR)
were calculated as total plaque area and set as
100%.
Volume analysis and quantification of Reelin-
positive and amyloid- plaques. Volumetric
analysis was performedwith theMercator soft-
ware (ExploraNova). Five to seven sections per
series were measured per animal. One hemi-
sphere (for plaque analysis) or individual brain
areas included in the volumetric assessments in
15-month-oldmice (i.e., neocortex, entorhinal
cortex, hippocampus) were delineated with a
2.5 objective (NA, 0.075). The volumes were
estimated according to the formula VA
tnom 1/ssf, where A is the summed area of
one hemisphere or brain area, tnom is the nom-
inal section thickness of 40 m, and ssf is the
section sampling fraction (1/12). Amyloid- plaques, classified as either
granular or fibrillar based on their morphology, were counted exhaus-
tively and their diameter measured within the neocortical layers I, II–VI,
entorhinal and piriform cortex, and hippocampus using a graphic tool of
Mercator. Reelin-positive neurons and plaques were counted exhaus-
tively within the outlined hippocampus using the 40 objective (NA,
1.3). The total number of neurons (N) and plaques (P) were estimated
according to the formula N or Ptot N or P 1/ssf, where N or P is
the sum of neurons or plaques, respectively.
Protein extracts and Western blotting. Dissected hippocampi and neo-
cortex samples (Table 1) were sonicated on ice in 10 vol of RIPA buffer
(20mMTris, 150mMNaCl, 1%TritonX-100, 1%Na-deoxycholate, 0.1%
SDS) containing protease (Roche; Mini Complete tablets) and phospha-
tase inhibitors (Sigma-Aldrich). Soluble and membrane-associated/in-
soluble fractionswere separated by centrifugation at 20,000 g at 4°C for
20min. Pellets were resolved in 70% formic acid and neutralizedwith 8N
NaOH. Total protein concentrations were measured with Bradford as-
says (Bio-Rad). Protein samples (20 g) were separated by SDS-PAGE
using 10–20% Tris-Tricine gels (Invitrogen), blotted onto Protran 0.1
m nitrocellulose (Sigma-Aldrich), and blocked in TBS containing 5%
Western blocking reagent (Roche) for 10 min to 1 h at room tempera-
ture. All Western blots were run in duplicate for semiquantitative
analysis. Primary antibodies [mouse anti--amyloid (clone 6E10;
1:1000), mouse anti-amyloid precursor protein A4 (clone 22C11;Mil-
lipore; 1:1000), rabbit anti-human phosphorylated Tau (phospho-T205;
1:1000), rabbit anti--actin (A2066; Sigma-Aldrich; 1:15,000)] were in-
cubated overnight at 4°C and visualized by the enhanced chemilumines-
cence reaction (GE Healthcare). Semiquantitative analyses of the
immunoreactive bandswere performed on digitalized films using ImageJ
software (National Institutes of Health, Bethesda, MD). Sum pixel
brightness values (i.e., integrated density) corrected for nonspecific
background and equal loading using -actin as a control were included
in the statistical analysis.
ELISA. Human-specific amyloid- 1-40 and 1-42 ELISA microtiter
plates were obtained from The Genetics Company, and the assays were
performed according to the manufacturer’s protocol. The 50 l samples
of the brain extracts (supernatant, pellet) of mutant and wild-type mice
(Table 1) were used and run in duplicate. After 30 min incubation in the
substrate solution [TMB (tetramethylbenzidine)/peroxide mixture], the
reaction was stopped and the absorption quantified using the Synergy
HT Multi-Mode Microplate Reader (BioTek Instruments) measuring
the difference at 450 and 650 nm.
Statistical analyses.All analyses were performedwith the software Stat-
View, version 5.0 (Abacus Concepts). ANOVA with age and genotype as
the main between-subjects factors was performed for the immunohisto-
chemical analyses of the GFAP, CD68, NeuN, and A/Reelin plaque
stainings. Fisher’s least significant difference (LSD) tests were used for
post hoc comparisons. Planned comparisons (app vs reln/app) withMann–
WhitneyU tests were used for the analysis of the total number of plaques
estimated separately for each brain region, the volumetric analysis of the
hippocampal formation and neocortex at 15 months of age, the levels of
full-length APP, sAPP/N-APP, -stubs, A40 and A42 (Western blot-
Figure 1. Early neuropathological changes in the hippocampus of heterozygous reeler (reln) mice. Immunoperoxidase label-
ings of hippocampal brain sections obtained from 3-month-old (A, B, E–H ) and 9-month-old (C, D) wt and heterozygous reeler
mice (reln). A, C, Aging-related reduction in Reelin immunoreactivity and concomitant appearance of Reelin-positive plaques
(enlarged view in C) in the CA1 stratum radiatum, lacunosum-moleculare (slm), and outer molecular layer (ml) of the DG in
9-month-old comparedwith 3-month-oldwtmice. The two boxes in A are enlarged in E and F to show the dense accumulation of
Reelin-positivecells in thestratumoriensandthedistinctneuropil staining in theslmandml, respectively, the latter likely representingthe
extracellularReelinsecretedfromperforantpathaxonalprojections.B,Reelin-positiveplaquesarealreadydetectableat3monthsofage in
heterozygous reelermice. Note the reduction in Reelin-immunoreactive cells in stratum oriens (box in B is enlarged in G) and selective
enrichment in plaques in the slm (arrow; box in B is enlarged inH ).D, Prominent accumulation of Reelin in amyloid-like plaques in the
subiculum, slm, and outerml at 9months of age. Scale bars:D, 500m;H, 20m.
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ting and ELISA), full-length Reelin and N-terminal Reelin, phosphoTau
(T205), as well as for the size and area fraction of colocalized Thioflavin
S and anti-A, and Thioflavin S and 1-syntrophin IR, respectively. The
two-sample Kolmogorov–Smirnov test was used for comparing plaques
size distribution in app and reln/app subjects.
One (of eight) app animal was excluded from
the statistical evaluation of the ELISA A42
levels since the measured value was 3 SD
above the mean. In addition, one 9-month-old
app subject (of six) did not show any
amyloid- plaque staining and was therefore
excluded for the statistical analysis of the Ree-
lin/A plaque segregation. Statistical signifi-
cance was set at p 0.05.
Results
Early neuropathological changes in the
hippocampus of reln mice
We recently reported a significant aging-
associated decline in Reelin expres-
sion and concomitant accumulation in
amyloid-like plaques, which colocalize
with murine proteolytic APP fragments
(Knuesel et al., 2009; Doehner et al.,
2010). We further showed that this pa-
thology was accompanied by a significant
reduction in cholinergic and GABAergic
basal forebrain projection neurons, the
latter known to selectively target Reelin-
positive interneurons in the hippocampus
(Madhusudan et al., 2009). Here, we
tested whether the impact of reduced Ree-
lin levels in heterozygous reeler knock-out
mice (reln) correlated with putative accel-
erated neuropathological changes in the
hippocampal formation. The immuno-
histochemical investigations confirmed
the age-dependent reduction in Reelin
expression and appearance of Reelin-
positive plaques in CA stratum radiatum
(sr), lacunosum-moleculare (slm), and
dentate gyrus (DG) molecular layer (ml)
in wt mice (Fig. 1A,C). Reelin IR in reln
mice was strongly reduced in hippocam-
pal GABAergic interneurons and neuropil
compared with wt littermates at all ages
investigated (Fig. 1A–D). Strikingly, al-
ready at 3 months of age, Reelin-positive
amyloid-like plaques were seen in the slm
of relnmice (Fig. 1B, arrows), whereas the
hippocampal formation was devoid of de-
posits in age-matched littermates (Fig.
1A,E,F). In agreement with our previous
findings (Knuesel et al., 2009), Reelin
plaques in wt mice appeared only around
9 months (Fig. 1C). Statistical evaluation
of the stereological estimates of the Reelin
plaque density confirmed the significant
difference between genotypes at 3 months
(supplemental Fig. 1A, available at www.
jneurosci.org as supplemental material).
At 9 months, however, the plaque density
was comparable between wt and reln
mice, suggesting a shift in the temporal
plaque profile between genotypes and an
acceleration of aging-related neuropathological changes in reln
versus wt mice (supplemental Fig. 1A,B, available at www.
jneurosci.org as supplemental material).
Figure 2. Early and accelerated amyloid-plaque deposition in reln/app double transgenic mice. Representative images of
coronal brain sections taken from 6- (A–C), 9- (D), and 15-month-old singlemutant (app) and doublemutant (reln/app)mice (E)
processed for anti-amyloid- immunoperoxidase staining. A, No amyloid- plaque deposition was detected in single transgenic
ADmice at 6months.B, In contrast, numerous amyloid- plaqueswere evident in both hippocampus and cortex of reln/appmice
at this age. C, Typical dense-core fibrillar plaque in the CA1 stratum oriens (so). C, Granular A plaque, potentially representing
precursor amyloid deposits in the DGmolecular layer.D, Representative images of half-brain sections of a single (left) and double
mutant (right) mouse processed for immunoperoxidase staining using 6E10monoclonal anti-A antibody. Note the increase in plaque
size and the prominent layer-specific localization of amyloid- plaques in the CA1 lacunosum-moleculare and piriform cortex layer I
(arrows) of reln/appmice. E, Representative brain sections of an app (left) and reln/app (right)mouse at 15months showing the aggra-
vated plaque load in reln/app mice compared with app subjects. Note the ventricular enlargement and reduced cortical thickness in
reln/appbrains, indicative of progressive neurodegeneration. Scale bars:A,D, E, 500m; C, 20m.
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Early amyloid- plaque deposition in reln/app double
transgenic mice
To assess whether reduced Reelin expression is also associated
with altered temporal and spatial amyloid- plaque pathol-
ogy, we created a mutant mouse line expressing 50% of the
reelin gene product in a transgenic AD background (see Ma-
terials and Methods), referred to as reln/app. Littermate con-
trols were either wt, heterozygous for reelin (reln), or
transgenic AD mice (app). Immunohistochemical and bio-
chemical experiments were performed across aging, ranging
from 3 to 15 months (Table 1). Anti-A immunohistochemistry
revealed no fibrillary amyloid- plaques at 3 months of age inde-
pendent of the genotype. Likewise, brain sections of 6-month-old
wt and reln mice were devoid of fibrillary amyloid- plaques
(data not shown). In line with previous reports (Knobloch et al.,
2007), we found no amyloid- plaques in the hippocampal for-
mation (Fig. 2A) and only very few in the neocortex (maximum
of one to two per section) in app mice at 6 months. This was in
contrast to reln/app littermates (Fig. 2B, arrows), in which
amyloid- plaques of different morphologies including fibrillar
and granular types (Fig. 2C) were evident in the hippocampus
and neocortex in all subjects, indicating accelerated amyloid-
plaque formation in Reelin-deficient AD mice. At 9 months,
amyloid- plaques were present in app mice throughout the
cortex but mostly missing in the hippocampus (Fig. 2D, left;
supplemental Fig. 1C,D, available at www.jneurosci.org as sup-
plemental material). In reln/app mice, however, the accumula-
tion of granular and fibrillary A IR was strongly increased,
strikingly selective in CA1 slm, DG ml, and piriform/entorhinal
cortex layer I (Fig. 2D, right, arrows; supplemental Fig. 1C,D,
available at www.jneurosci.org as supplemental material), nota-
bly areaswith highest Reelin IR inwtmice (Fig. 1A). Stereological
analysis of the plaque load at 9 months revealed a significant
increase in plaque size and a corresponding significant increase in
the number of large (75mindiameter) granular and fibrillary
plaques in hippocampus and cortical layer I of reln/app com-
pared with app subjects (Table 2). In line, the cumulative size
distribution revealed a significant shift toward larger plaques
(supplemental Fig. 1E–H, available at www.jneurosci.org as sup-
plementalmaterial) (Dmax ranging from0.18 to 0.37,Kolmogorov–
Smirnov test), despite comparable numerical densities of
small- (25 m) and medium-sized plaques (25–75 m) be-
tween genotypes (Table 2). We also observed some strikingly
large fibrillary and granular plaques in cortical layers II–VI
(supplemental Fig. 1C,D, available at www.jneurosci.org as
supplemental material); however, the overall number, mean
size, as well as the cumulative size distribution of amyloid-
plaques were not different between genotypes in these cortical
layers. At 15 months, amyloid- plaque density further in-
creased and remained significantly higher in reln/app com-
pared with app mice throughout the hippocampal formation
and cortex (Fig. 2E). At this age, app mice also showed
amyloid- plaques in the subiculum and CA1 slm, most
prominently seen in the temporal pole of the hippocampus.
However, in reln/app mice, these layers were almost com-
pletely covered by amyloid- IR along the entire septal-
temporal axis. Moreover, signs of massively enlarged
ventricles and a distinct shrinkage in cortical thickness were
evident in reln/app mice at 15 months (three of three). Quan-
titative volumetric analysis of the hippocampus (along its en-
tire septo-temporal axis) and cortex (including piriform,
entorhinal, motor and somatosensory areas) revealed a signif-
icant volume reduction in 15-month-old reln/app (hip,
10.1  1.5 mm3; ctx, 28.3  1.5 mm3) compared with app
mice (hip, 13.8  1.1 mm3; p  0.029; ctx, 33.3  1.5 mm3;
p  0.017). Volumetric reductions in the whole hippocampal
formation of reln/app mice approached a difference of26%
compared with app, whereas neocortical areas were less af-
fected (9%). The ventricle enlargement in the posterior part
was also significantly larger in reln/app compared with app
(11.8%; p  0.049; Mann–Whitney U test; values are
mean SD). Together, these results indicate that a reduction
in Reelin expression significantly accelerates A deposition
and promotes neurodegeneration in aged transgenic ADmice.
Increased inflammatory responses in double transgenic mice
Neurodegeneration is tightly linked to inflammation, a process
that is characterized by the presence of activated microglia and
reactive astrocytes around amyloid- plaques and increased lev-
els of inflammatory mediators (Wyss-Coray, 2006). To test
whether the accelerated formation and size increase of amyloid-
plaques in double mutant mice were accompanied by enhanced
inflammatory changes, we used markers for activated micro-
glia (CD68) and astrocytes (GFAP) combined with anti-A
or -Reelin immunohistochemistry (Fig. 3A–F). In line with the
amyloid- pathology, GFAP and CD68 IR in hippocampus and
cortex at 6 months were only moderately higher in reln and reln/
app compared with wt and app mice (Fig. 3G,H). In contrast, at
9 months of age, both astrocytes and microglia levels were
significantly enhanced in reln/app mice compared with app
subjects and revealed a pronounced association with
amyloid- as well as Reelin-positive plaques in cortex and hip-
Table 2. Stereological estimates of amyloid- plaques in 9-month-old single and
double transgenic ADmice
app reln/app p
Hippocampus
Granular
Small 175 84 224 81 0.35
Medium 125 45 249 69 0.15
Large 0 0 11 4** 0.01
Fibrillar
Small 434 161 1014 313 0.15
Medium 247 82 604 175 0.20
Large 3 2 38 17* 0.04
Cortex layer I
Granular
Small 127 57 158 49 0.35
Medium 87 31 194 53 0.15
Large 0 0 6 3 0.08
Fibrillar
Small 514 183 1142 316 0.16
Medium 297 86 600 136 0.10
Large 5 4 39 17* 0.04
Cortex layers II–VI
Granular
Small 106 42 105 50 0.82
Medium 79 32 114 26 0.38
Large 3 2 6 5 0.99
Fibrillar
Small 382 130 960 279 0.11
Medium 243 91 543 113 0.06
Large 21 13 42 11 0.12
Values are presented as mean (SEM) for the quantification of the estimated number of granular and fibrillary
amyloid- plaques, classified as either small (25m), medium (25–75m), or large (75 mm in diameter),
and expressed as total number in the given brain area of app and reln/app (n 8) subjects. Plaque counts in the
hippocampus were performed along its entire septo-temporal axis; numerical estimates in the cortex included the
piriform, lateral entorhinal, as well as the neocortex. *p 0.05, **p 0.01.
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pocampus (Fig. 3C,F). Interestingly, despite the presence of amyloid-
plaques in app mice, the levels of GFAP and CD68 IR were moderate
andnotdifferent fromwt littermates (Fig.3G,H), suggesting theabnor-
mal activation of microglia and astrocytes because of the exacerbated
amyloid-plaque pathology in reln/appmice.
Aggravated amyloid- plaque pathology in reln/app mice
To investigate further the progression of reactive astrocytes,
amyloid- and Reelin IR in reln/app mice, we performed high-
magnificationconfocal imagingof triple-labeledbrain sectionsof 6-,
9-, and 15-month-old mice. We found a prominent elevation in
GFAP IR surrounding granular amyloid-plaques in reln/appmice
across aging that was accompanied by a significant enlargement of
individual granules and increased colocalizationbetweenamyloid-
and Reelin IR in granular plaques (sup-
plemental Fig. 2A,B, available at www.
jneurosci.org as supplemental material). In
contrast, granular plaque pathology in app
subjectswasmuch less pronounced, as indi-
cated by the moderate GFAP, A, and Ree-
lin IR in CA1 area at 9 months of age
(supplemental Fig. 2C, available at www.
jneurosci.org as supplemental material).
Fibrillary A plaques in 6-month-old
reln/app mice were already densely sur-
rounded by astrocytes, particularly prom-
inent in the hippocampus, pointing again
to the advanced stage in amyloid- plaque
formation (supplemental Fig. 2E, avail-
able at www.jneurosci.org as supplemen-
tal material). A similar pattern was seen in
the neocortex; however, astrogliosis was
much less advanced compared with the
hippocampal formation (supplemental
Fig. 2D, available at www.jneurosci.org
as supplemental material). Interestingly,
prominent Reelin IR was associated with
fibrillary plaques, correlating with their
size and showing partial colocalization
with A (supplemental Fig. 2E, arrows,
available at www.jneurosci.org as supple-
mental material), again a feature being
much less pronounced in app compared
with the reln/app subjects. At 9 months of
age, Reelin IR further increased in area
and intensity, most prominently in fibril-
lary plaques in the cortex and CA1 slm
(Fig. 4) of reln/app mice, whereas
plaque pathology in app littermates re-
sembled the pattern seen in 6 month
reln/appmice (Fig. 4A; supplemental Fig.
2D, available at www.jneurosci.org as sup-
plemental material). Moreover, Reelin-
positive plaques appeared to segregate from
amyloid- plaques in hippocampus and
cortex of reln/app but not age-matched
app mice (Fig. 4H). Quantitative analysis
of the area covered by Reelin and A
plaques confirmed the increase in Reelin
IR in extracellular deposits (supplemental
Fig. 3, available at www.jneurosci.org as
supplemental material) and revealed a
significantly lower overlap and higher lev-
els of segregation between Reelin and A IR in extracellular
plaques in reln/app compared with appmice. These results point
to a potential bidirectional facilitation of aggregation between
Reelin and amyloid- peptides. At 15 months, the additional
increase in plaque pathology in reln/app mice was mirrored by a
selective reduction in neuronal density, accompanied by a mas-
sive coverage by activated astrocytes andmicroglia occupying the
neuropil surrounding amyloid- deposits (Fig. 4M–O), a phe-
nomenon likely underlying the volumetric reductions of cortical
areas measured in reln/app mice at this age (Fig. 2E). In app
littermates, no evidence for a significant reduction in neuronal
numbers in the vicinity of amyloid- plaques was evident (Fig.
4K), and, correspondingly, glia activation was not as high as in
double mutants (Fig. 4J). Quantitative evaluation of the neuronal
Figure 3. Increased inflammatory responses in reln/app double transgenic mice. Low-magnification images of double immu-
nofluorescence staining of cortical (A–C) and hippocampal (D–F ) brain sections obtained from 9-month-old single mutant app
and double mutant reln/app mice. A, B, D, E, Pronounced increase in GFAP-positive astrocytes (red) selectively associated with
amyloid- plaques (anti-A1-40/42 antibody; green)was found in reln/app comparedwith app subjects. C, F, A similar increase in
reactive microglia was evident in the neocortex (C) and hippocampus (F ) of 9 month reln/appmice. Note the selective accumula-
tion of CD68-positive microglia (red) with Reelin-immunoreactive plaques (green). G, Quantification of the area fraction of GFAP-
immunoreactive astrocytes revealed a main effect of genotype (F(3,20) 4.4; p 0.016) and significant differences between
reln/app versus wt ( p 0.022), reln/app versus reln ( p 0.043), and reln/app versus app ( p 0.010) at 9 months of age.H,
Similar differences emerged between reln/app versuswt ( p 0.039) and reln/app versus app ( p 0.046) subjects for the CD68
area fraction. Values are given as mean SEM. *p 0.05 (comparison with reln/app subjects), statistical significance based on
Fisher’s LSD post hoc analysis. Scale bars: C, 50m; F, 10m.
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density around amyloid- plaques using
NeuN immunohistochemistry supported
this observation and revealed a significant
reduction in NeuN-positive neurons in
reln/app versus app subjects (supple-
mental Fig. 4A–D, available at www.
jneurosci.org as supplemental material),
suggesting that the reduction in Reelin-
mediated signaling and the elevation in
inflammatory markers significantly con-
tribute to progressive neurodegeneration
in aged reln/app mice.
Increase in amyloidogenic APP
processing and insoluble A
species in double mutants
In vitro data revealed reduced amyloido-
genic APP processing in the presence of
Reelin in the culture medium (Hoe et al.,
2006). To test whether the aggravation
in amyloid- plaque pathology was ac-
companied by enhanced production
and increased A peptide levels, we per-
formed Western blot analysis and ELISA
of SDS-soluble and -insoluble, formic
acid-extracted fractions of hippocampal
and cortical brain lysates of app and reln/
app mice. In the soluble fraction, en-
hanced amyloidogenic APP processing in
reln/app versus app was evident, as indi-
cated by the presence of A species and
the increase in -secretase-cleaved APP
ectodomains (sAPP) andC-terminal frag-
ments (-stubs) in the hippocampus of
reln/app mice compared with app sub-
jects (Fig. 5A–D). Semiquantitative analy-
sis of the immunoreactive bands in the
soluble fractions revealed significantly
higher levels of -stubs and sAPP in the
double mutants compared with the sin-
gle transgenic AD mutants (Fig. 5B–D).
Surprisingly, we also observed elevated
levels of N-terminal APP fragments, in-
versely correlating with the expression
levels of full-length Reelin (Fig. 5C,G),
further confirming that reduction in
Reelin expression alters proteolytic pro-
cessing of APP. The insoluble fractions
of both hippocampal and cortical brain
lysates of reln/app mice contained sub-
stantial amounts of A species (Fig. 5E).
Quantitative analysis using ELISA con-
firmed this observation and revealed
significant increases in insoluble A40
and A42 peptides in both hippocam-
pus and cortex in reln/app compared
with app littermates (Fig. 5F ). Together,
these results suggest that reduction in
Reelin increases A levels by favoring
amyloidogenic APP processing and by
promoting aggregation of A peptides
in the neuropil of the hippocampus and
cortex.
Figure 4. Aggravation and segregation of Reelin and amyloid- plaques pathology in the hippocampus and cortex of 9- and
15-month-old double mutant reln/app mice. A–I, Triple immunofluorescence stainings using Cy3-GFAP (red), anti-A1-40/42
(green), and anti-Reelin (blue) antibodies on cortical (A–F ) and hippocampal (G–I ) brain sections of 9-month-old app (A–C) and
reln/app mice (D–I ). In the double mutants, amyloid- plaques were densely surrounded and tightly associated with reactive
astrocytes, whereas in app subjects only moderate astrogliosis was evident. Note the intense Reelin immunoreactivity associated
with fibrillary amyloid- plaques (B vs E, arrows) and their striking segregation from A deposits (H, arrow) in the CA1 slm in
reln/app compared with app subjects. J–O, Aggravation of the microgliosis and astrogliosis in reln/appmice at 15 months of age
was particularly prominent in the entorhinal cortex (ECtx). Note the reduction in APP-expressing neurons in the aged double (N )
versus single mutants (K ). Scale bars: C, F, I, 10m; L, O, 20m.
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To investigate further the accelerated aggregation state, we
compared the density of fibrillary A species between geno-
types using Thioflavin S staining in combination with anti-A
immunohistochemistry (6E10). In addition, we used an antibody
against 1-syntrophin, a marker for astrocytic endfeet, to inves-
tigate a putative preferential association of A plaques with cere-
bral perivasculature. In agreement with our biochemical
measurements, we detected a significant increase in the number
and size of Thioflavin S-positive fibrillary aggregates in all brain
areas investigated, including neocortical and hippocampal for-
mation in reln/app versus app subjects (Fig. 6A–C). Moreover,
the area covered by A- and Thioflavin S-positive signals in these
brain regions was significantly larger in reln/app compared with
app mice (Fig. 6D), supporting the view that the reduction in
Reelin expression facilitates and accelerates the formation of
fibrillary A species. No difference with respect to neuropil ver-
sus vascular amyloidosis was found between genotypes (all p 
0.6), indicating that the increase in A plaque deposition in reln/
app mice was not associated with a preferential increase in
-amyloid angiopathy.
Abundant dystrophic neurites and elevation of phospho-Tau
in aged reln/app mice
In addition to direct binding to APP and modulating its proteo-
lytic processing (Hoe et al., 2006, 2009), Reelin-mediated signal-
ing inhibits keymediators of Tau phosphorylation (Hiesberger et
al., 1999; Beffert et al., 2002, 2004; Ohkubo et al., 2003). We
therefore reasoned that genetic reduction in Reelin expres-
sion—in addition to favoring amyloidogenic APP processing—
might promote hyperphosphorylation of Tau and facilitate the
formation of neurofibrillary tangles in aged subjects. We there-
fore performed biochemical and immunohistochemical analysis
to assess the levels of phospho-Tau using an antibody raised
against phosphoT205 across aging. In young and adult brain tis-
sue, highest phospho-Tau levels can be detected in axonal pro-
jections throughout the brain, particularly prominent in mossy
fibers and terminals in stratum lucidumof theCA3 area (data not
shown). At 9 months of age, biochemical analyses revealed a
significant elevation of phospho-Tau levels in hippocampal and
cortical brain lysates of reln/app compared with app mice (sup-
plemental Fig. 4E–G, available at www.jneurosci.org as supple-
Figure 5. Increase in amyloidogenic APP processing and insoluble A levels in doublemutant reln/appmice. A, RepresentativeWestern blots of the SDS-soluble supernatant (SN) derived from
hippocampal brain lysates of 9-month-oldmice using anti-A (6E10) antibodies.B, Semiquantitative analysis involving densitometry of the immunoreactive-cleaved C-terminal APP fragments
(-stubs), run in duplicate, corrected for nonspecific background and equal loading using-actin as control, revealed a significant increase in reln/app compared with app ( p 0.049; n 4).
Soluble A-levelswere very low, but clearly detectable in samples of reln/app subjects. C, RepresentativeWestern blots using anti-Reelin (G10) antibody recognizing both full-length (FL-Reln) and
theN-terminal 180kDa fragment (N-Reln). TheN-terminal-specific APPantibody (22C11) antibody recognized in addition to full-lengthAPP (FL-APP) and the soluble- or-secretase-cleavedAPP
ectodomains (sAPP) short N-terminal fragments, presumably representing N-APP. D, Statistical analysis of the densitometrical measurements of FL-APP and sAPP-immunoreactive fragments
revealed a significant difference between genotypes as indicated by the reduced FL-APP/sAPP ratio in reln/app comparedwith app subjects ( p 0.033; n 4). In addition, amarked shift toward
higher N-APP-immunoreactive fragments in 9-month-old reln/app mice was evident, as demonstrated by the significant reduction in the FL-Reelin/N-APP ratio (G) ( p 0.034; n 4). E,
Representative Western blots using anti-A (6E10) antibodies of SDS-insoluble fractions (pellet) of hippocampal brain lysates, which was resuspended in formic acid (FA). F, Quantitative analysis
using ELISAwithA40- andA42-specific antibodies revealed a significant increase inApeptides in the insoluble fractions of reln/app comparedwith app littermates in the hippocampus (A40,
p 0.021; A42, p 0.046) and neocortex (A40, p 0.016; A42, p 0.016; n 7–8). Values are expressed as fraction of total protein content and given as mean SEM. *p 0.05
**p 0.01, statistical significance based on Mann–Whitney U test.
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mental material), confirming that Reelin-
mediated signaling in aged subjects
remains a major modulator of Tau phos-
phorylation as described during neurode-
velopment (Beffert et al., 2002; Brich et al.,
2003). In line with these biochemical data,
several neurons with distinct anti-
phospho-Tau signals in the soma were
detectable, sparsely distributed in plaque-
dense areas in the hippocampal formation
and neocortex in 9-month-old reln/app
but not in appmice (data not shown). At 15
months of age, a striking concentric accu-
mulation of phospho-Tau-positive cells
selectively associated with amyloid-
plaques was evident in reln/app. High-
magnification confocal microscopy re-
vealed a distinct anti-phospho-Tau IR
enriched in neuronal somata and dendrites
(Fig. 7B, arrow, inset). Littermate app mice
at the sameage showedsomeanti-phospho-
Tau IR; however, this was mostly restricted
to extrasomatic sites, likely representing ax-
onal localization (Fig. 7A, inset). Typically,
the area surrounding the plaques also con-
tained pronounced anti-amyloid- IR in
reln/app compared with app mice at 15
months (Fig. 7A–B), suggesting that hy-
perphosphorylation of Tau in soma and
dendrites is selectively promoted around
amyloid- plaques, potentiallymediated by
reduced Reelin and elevated nonfibrillary
A levels, and/or glia cells and their se-
creted inflammatory cytokines.
A highly similar picture emerged using
immunoperoxidase labelings. Both corti-
cal and hippocampal neurons associated
with amyloid- plaques in reln/app but
not appmice showed strong somatic anti-
phospho-Tau IR (Fig. 8A,B, inset). Interestingly, some of them
stood out by the presence of distinct phospho-Tau aggregates,
suggestive of degenerating neurons (Fig. 8C, inset). This was also
evident in the hippocampus, particularly prominent in the
CA1 slm and sr, where we detected typical tangle-like struc-
tures (Fig. 8D, inset), indicating the presence of neurofibrillary
depositions in aged double mutants. To confirm the presence of
this typical AD-like neuropathological hallmark and to assess
putative neurodegeneration associated with amyloid- plaques,
we performed also Gallyas silver staining. At 9 months of age,
no indication of neurodegenerative processes nor tangle-like
aggregates were evident in reln/app and appmice (data not shown).
At 15 months, selectively in reln/app subjects, bright-field micros-
copy revealed the presence of distinct silver precipitates selectively
associated with amyloid- plaques, which likely represent dystro-
phicneurites (Fig. 8F,G).This featurewasmostprominently seen in
the entorhinal cortex, accompanied by densely labeled cell bodies
andneurites surrounding the plaques in the doublemutants but not
appmice (Fig. 8E). In line with the anti-phospho-Tau immunohis-
tochemistry, individual silver-stained intracellular aggregates were
detected in the entorhinal cortex of reln/app mice within the dys-
trophic compartment, suggesting the presence of neurofibril-
lary tangles selectively associated with amyloid- plaques in
aged Reelin-deficient AD mice.
Together, the findings indicate that a genetic reduction in
Reelin expression accelerates the production of amyloidogenic
A peptides, which results in earlier plaque formation and an
age-related aggravation of the pathology including early signs of
neurodegeneration in hippocampal formation and cortex of AD
mice that is accompanied by elevated phospho-Tau levels and
neurofibrillary tangle formation in aged subjects.
Discussion
The present study provides convergent immunohistochemical
and biochemical evidence that a genetic reduction in Reelin
expression favors amyloidogenic APP processing in vivo, re-
sulting in precocious formation and age-related aggravation of
amyloid- plaque pathology, accompanied by concentric accu-
mulation of phospho-Tau-positive neurons, neurofibrillary tan-
gles, and neurodegeneration in the hippocampal formation. The
animal model thereby unites for the first time amyloid- plaque
and Tau pathology in a temporal and spatial pattern that closely
recapitulates the progression of AD neuropathology in humans
(Braak and Braak, 1996), importantly in the absence of tau mu-
tations. Furthermore, it complements several previous studies
involving genetic studies (Brich et al., 2003), in vitro experiments
(Hoe et al., 2006), and in vivo neuronal survival assays (Beffert et
al., 2006b) demonstrating that dysfunctional Reelin-mediated
Figure 6. Increase in Thioflavin S-positive amyloid- plaques in reln/app mice in neocortex and hippocampal formation.
Double immunofluorescenceusinganti-A (6E10; red) andanti-1-syntrophin (Syn; blue) antibodies combinedwithThioflavin
S counterstaining (green) were performed to investigate the fibrillary amyloid- plaque load in both neuropil and cerebral
vasculature in 9-month-old app (A) and reln/appmice (B). Note the increase in Thioflavin S signals concomitantlywith theanti-A
immunoreactivity in the outer layers of the neocortex. C, Densitometric analysis of the brightness and surface area covered by
Thioflavin S-positive signals in the neocortical layers I–VI (Ctx), lateral entorhinal cortex (EC), and dorsal and ventral hippocampus
(Hip). D, Quantification of the pixel overlap between the green Thioflavin S-positive signals and red anti-A immunoreactive
staining, averaged frommeasurements of eight images (512512pixel in size) per animal andbrain region (n4pergenotype)
acquired in the areas indicated. Values are given as mean SEM. *p 0.05, statistical significance based on Mann–Whitney U
test. Scale bar, 50m.
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signaling through ApoER2 acts as a critical upstream modulator
of amyloidogenic APP processing, Tau hyperphosphorylation,
and neuronal survival, presumed to underlie AD-associated
neuropathology.
Our comprehensive investigations across aging revealed a
significantly accelerated extracellular A neuropathology in
Reelin-deficient AD mice, as indicated by the presence of
amyloid- plaques in hippocampus and neocortex as early as 6
months. Littermate app mice were virtually devoid of amyloid-
deposits at this age, in line with the original report (Knobloch et
al., 2007). At 9 and 15 months, pathology was further aggravated
in reln/app mice, resulting in a striking redistribution and selec-
tive accumulation of A plaques in entorhinal projection areas,
precisely corresponding to areas in which Reelin IR is enriched in
extracellular plaques in reln but not app littermates (Figs. 1, 2).
Moreover, we detected numerous A plaques in layer I of the
entorhinal, piriform, and neocortex, again in areas with strong
Reelin expression in young andReelin plaque depositions in aged
subjects (Knuesel et al., 2009). A plaques were also significantly
larger in these areas in double compared with single mutants,
affecting both granular (presumable nonfibrillary, soluble depos-
its) as well as fibrillary plaques (Table 2, Figs. 2, 6; supplemental
Fig. 1E–H, available at www.jneurosci.org as supplemental ma-
terial). Biochemical investigations using SDS-soluble fractions of
hippocampal and cortical lysates revealed significant decrease in
full-length APP and concomitant increases in -secretase-
cleaved APP ectodomains (sAPP), C-terminal fragments
(-stubs), and A peptides (Fig. 5), indicating elevated amyloi-
dogenic APP processing, in line with previous in vitro data (Hoe
et al., 2006; Hoe and Rebeck, 2008). Western blotting and quan-
titative ELISA of formic acid-extracted
hippocampal and cortical brain lysates re-
vealed also significantly higher levels of
insoluble A40/42 peptides in reln/app
compared with app littermates (Fig. 5),
confirming that reduced Reelin levels, po-
tentially by altering APP trafficking,
membrane insertion, and favoring
-secretase cleavage (Hoe et al., 2006),
enhances A production. It is further
conceivable that reduction in Reelin-
signaling promotes APP endocytosis be-
cause of reduced binding of the central
Reelin domain to the N terminus of APP
(Hoe et al., 2009). This scenario fits with
previous data showing preferential APP
-secretase cleavage in endocytic vesicles
(Rajendran et al., 2006, 2008), in line with
the reported endosomal localization and
pH optimum of -secretase activity (Vas-
sar et al., 1999).
In addition to the role of reduced
Reelin-mediated signaling on amyloido-
genic APP processing, our data also sug-
gest a direct effect on A aggregation. We
show that a reduction inReelin expression
favors its own aggregation, as demon-
strated by the significantly earlier but
highly conserved Reelin plaque pathology
(Knuesel et al., 2009) in reln compared
with wt mice (Fig. 1). Thus, it is conceiv-
able that both reduced Reelin-dependent
signaling promoting A production as
well as Reelin aggregation by providing a nucleation site for
aggregation-prone peptides, results in aggravation of the
amyloid- plaque phenotype. Indeed, we observe an overlap
between Reelin and amyloid- plaques in LI of the entorhinal
cortex and perforant path axonal projection sites where the
two selectively associate and partially colocalize in granular and
fibrillary plaques (Fig. 4; supplemental Fig. 2, available at www.
jneurosci.org as supplemental material). Interestingly, we also
detected a segregation of Reelin IR from A-positive fibrillary
plaques in aged reln/appmice, indicating that aggregation of Ree-
lin itself aggravates in the vicinity of amyloid- plaques and re-
active glia. This phenomenon was again more prominent in the
hippocampal formation comparedwith neocortical regions, con-
firming the increased vulnerability of this brain area with respect
to AD-like neuropathology. A reciprocal effect is also conceiv-
able, withA peptides promoting Reelin aggregation. Support for
this hypothesis has been recently provided by Botella-Lo´pez et al.
(2010), demonstrating that amyloid-peptides can alterReelinpro-
cessing and glycosylation, critical modifications demonstrated to be
required for proper Reelin-mediated signaling (Lambert de Rou-
vroit et al., 1999; Koch et al., 2002; Jossin et al., 2007) and potentially
involved in abnormal oligomerization and aggregation of Reelin
(Utsunomiya-Tate et al., 2000; Kubo et al., 2002; Yasui et al., 2007).
Difference in plaque pathology between genotypes was also
associated with distinct inflammatory responses in reln/app ver-
sus appmice. Our investigations of reactive glia revealed a signif-
icant aging-related increase in GFAP and CD68 IR, tightly
intermingledwith amyloid- plaques in reln/appmice (Figs. 3, 4;
supplemental Fig. 2, available at www.jneurosci.org as supple-
mental material). In contrast, A plaques were detected without
Figure 7. Selective association of anti-phospho-Tau immunoreactivity in plaque-dense areas within CA1 slm. A, B, Double
immunofluorescence using anti-phospho-T205 (red) and anti-A (6E10, blue) antibodies combined with Sytox Green nuclear
counterstaining to investigate the relationship between amyloid- plaque and Tau pathology in app (A) and reln/app (B) at 15
months of age. A, Representative amyloid- plaque in the CA1 slm of app mice with a dense core and some diffuse anti-A
immunoreactivity surrounding it (A). In line with the immunoperoxidase stainings, anti-phospho-Tau immunoreactivity in app
subjectswas readily detectable in the neuropil, but no evidence for any enrichment in cells surrounding the plaqueswas found (A",
enlarged view is shown in inset). B–B, Anti-amyloid- immunoreactivity covered large areas within the core and surrounding
areas of plaques in the CA1 slm of reln/app mice. Note the selective fibrillary enrichment of anti-phospho-Tau signals in the
cytoplasm (inset) and dendrites (arrow) of neurons selectively associatedwith amyloid plaques. The distinct spatial distribution of
the amyloid- and Tau pathology is also evident on the xz and yz view at the bottom and right side of the image. Scale bars: A, B,
30m.
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or weak GFAP/CD68 IR in app littermates (Fig. 3). In line with
the biochemical data, these findings support our interpretation of
a significantly more aggravated and advanced fibrillary plaque
pathology in aged reln/app compared with app mice. This is in
agreement with immunohistochemical studies examining the
brains of AD patients (McGeer et al., 1987), as well as with nu-
merous studies using different animal models of AD (for review,
see El Khoury and Luster, 2008), demonstrating that microglia
accumulation in senile plaques is an integral part of AD patho-
genesis. Our data also fit with recent findings showing that the
phenotype of accumulatingmicroglia changes as AD-like pathol-
ogy progresses in tgAPP-PS1mice (Hickman et al., 2008), from a
protective, A-clearing role during early phases to an enhanced
production in inflammatory cytokine and loss in A-clearing
capabilities during later disease phases. Furthermore, it is con-
ceivable that, in addition to dysfunctional Reelin signaling,
proinflammatory cytokines including interferon-, TNF- (tu-
mor necrosis factor-), and interleukin-1, shown to be secreted
fromglia (Hickman et al., 2008) and demonstrated to be involved
in -secretase upregulation (Yamamoto et al., 2007) and
-secretase-mediated APP cleavage (Liao et al., 2004), contribute
to A production and accumulation.
The elevated release of proinflammatory cytokines by A-
activated glia is also expected to promote neurodegenerative pro-
cesses (Blurton-Jones and Laferla, 2006; Chiarini et al., 2006).
However, neurodegeneration in turn strongly promotes gliosis.
Indeed, at 15 months, amyloid- plaque pathology was accom-
panied by striking and significant reduction in neuronal density,
accompanied by strong astrogliosis and dystrophic neurites sur-
rounding the plaques in reln/app, whereas app littermates
showed only very mild signs of plaque-associated neurodegen-
eration (Fig. 8). Moreover, a significant ventricular enlargement
and shrinkage of cortical areas, mostly affecting the hippocampal
formation, was evident in double compared with single mutants
(Fig. 2), indicating that reduced Reelin levels by promoting A
plaque deposition and inflammatory responses, result in neuro-
degeneration in aged subjects. A potential molecular mechanism
has been recently provided by the findings that signaling through
a spliced isoform of the Reelin receptor ApoER2 is essential for
protection against neuronal cell loss during normal aging (Beffert
et al., 2006b), pointing to an exciting mechanistic link between
Reelin deficiency and neurodegeneration through dysfunctional
ApoER2 signaling. However, we cannot rule out completely that
subtle neuroanatomical changes occurring in relnmicemay con-
tribute to the observed neuropathology in reln/app mice. How-
ever, considering that we did not detect statistical differences in
volume and neuronal density between genotypes up to 9 months
of age, we consider this putative confounding factor as unlikely.
Another striking effect accompanying these neuropathologi-
cal changes was the concentric accumulation of phospho-Tau-
positive neurons around senile plaques in reln/app mice (Figs. 7,
8), supporting previous genetic interaction studies demonstrat-
ing a critical role of Reelin-mediated signaling via Dab1 phos-
phorylation in inhibiting Tau hyperphosphorylation (Brich et al.,
2003). Interestingly, although neocortical neurons contained
mainly cytoplasmic anti-phospho-Tau IR, distinct tangle-like
structures were found in the hippocampal formation (Fig. 8), in
line with the more advanced plaque pathology in this brain re-
Figure 8. Concentric accumulations of phospho-Tau-positive neurons and neurofibrillary tangles around amyloid- plaques in 15-month-old reln/app mice. Representative images of brain
sections obtained from app (A, E) and reln/app mice (B–D, F, G) processed for immunoperoxidase staining using anti-phospho-T205 antibody (A–D) or silver staining (E–G). A, In app subjects,
uniformphospho-Tau immunoreactivitywas evident in the cortical neuropil, indicative of axonal localization. No particular enrichmentwas seen in the vicinity of amyloid- plaques, recognized by
their lack of phospho-Tau immunoreactivity (asterisk).B, C, In reln/appmice, strongly stained phospho-Tau-positive neurons were evident around amyloid- plaques in neocortical areas (insets).
D, In the hippocampus of reln/appmice, a similar patternwas evident in close vicinity to plaques; someneurons appeared dystrophic, strongly suggestive of tangle-like intraneuronal accumulations
(D, inset). E, Silver staining revealed some dark precipitates (arrowhead) in the vicinity of large plaques (asterisk) in the entorhinal cortex of app mice. F, In contrast, dense silver precipitates
surrounding amyloid- plaques, indicative of dystrophic neurites, were very prominent in reln/app mice. In addition, black-labeled intraneuronal aggregates, likely representing neurofibrillary
tangles, were seen in neurons associated with these plaques (arrows; enlarged in the insets). G, Representative image of a large amyloid- plaque in the entorhinal cortex of a reln/app mouse,
showing a concentric pattern of silver-stained cells, likely representing degenerating neurons in the vicinity of plaques (arrowheads). Scale bars, 20m.
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gion in double versus single mutants. Silver staining revealed the
presence of neurofibrillary tangle-like structures, selectively asso-
ciated with dystrophic neurites surrounding the plaques in the
entorhinal cortex, importantly in nontransgenic tau mutants.
The temporal and spatial aspects of the neuropathology supports
the critical upstream role of dysfunctional Reelin-mediated sig-
naling that is sufficient to accelerate amyloid- peptide produc-
tion in the hippocampal formation, which in turn promotes Tau
phosphorylation and tangle formation, selectively in plaque- and
glia-dense areas. This is in line with the current hypothesis of a
upstream role of A species with respect to Tau pathology
(Selkoe, 2000; Hardy and Selkoe, 2002; Walsh and Selkoe, 2004)
and with the findings from postmortem AD tissue showing a
distinct temporal and spatial progression of the neuropathology
in humans (Braak and Braak, 1996).
In conclusion, the data revealed for the first time in vivo that
reduced expression of Reelin has a significant effect on amyloi-
dogenic APP processing and amyloid- plaque deposition as well
as neurofibrillary tangle formation in the hippocampal forma-
tion of aged transgenic AD mice with a genetic reduction in the
reeler gene. Considering that Reelin is also an important modu-
lator of adult NMDA receptor-mediated neurotransmission and
synaptic plasticity (Weeber et al., 2002; Beffert et al., 2005, 2006a;
Chen et al., 2005; Qiu et al., 2006; Qiu and Weeber, 2007), a
stronger decline than normally seen during aging is expected to
trigger a cascade of downstream events, resulting in the shift from
nonamyloidogenic to amyloidogenic pathways, accompanied by
immunological changes, Tau hyperphosphorylation, and neuro-
fibrillary tangle formation, which presumably underlie the pro-
gressive neurodegeneration and cognitive decline associated with
late-onset AD.
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